Early Mortality among Patients with Head and Neck Cancer Diagnosed in Thuringia, Germany, between 1996 and 2016—A Population-Based Study

GND
1275151620
ORCID
0000-0002-4822-907X
Zugehörigkeit
Department of Otorhinolaryngology, Jena University Hospital, 07747 Jena, Germany;
Kouka, Mussab;
GND
135983371
ORCID
0000-0001-7242-5727
Zugehörigkeit
Department of Otorhinolaryngology, Suedharzklinikum Nordhausen, 99734 Nordhausen, Germany;
Buentzel, Jens;
GND
113902123
Zugehörigkeit
Department of Otorhinolaryngology, Helios-Klinikum Erfurt, 99089 Erfurt, Germany;
Kaftan, Holger;
GND
122024060
Zugehörigkeit
Department of Otorhinolaryngology, SRH Zentralklinikum Suhl, 98527 Suhl, Germany;
Boeger, Daniel;
ORCID
0000-0002-9820-5527
Zugehörigkeit
Department of Otorhinolaryngology, SRH Wald-Klinikum Gera, 07548 Gera, Germany;
Mueller, Andreas H.;
GND
141457325
Zugehörigkeit
Department of Radiotherapy and Radiation Oncology, Jena University Hospital, 07743 Jena, Germany;
Wittig, Andrea;
GND
172365473
Zugehörigkeit
Department of Oromaxillofacial Surgery and Plastic Surgery, Jena University Hospital, 07747 Jena, Germany;
Schultze-Mosgau, Stefan;
GND
1246219492
ORCID
0000-0003-2147-489X
Zugehörigkeit
University Tumor Center, Jena University Hospital, 07747 Jena, Germany;
Ernst, Thomas;
GND
1078441464
ORCID
0000-0001-9671-0784
Zugehörigkeit
Department of Otorhinolaryngology, Jena University Hospital, 07747 Jena, Germany;
Guntinas-Lichius, Orlando

Simple Summary When we consider the outcome of cancer treatment, we mostly focus on overall survival: studies on early mortality in head and neck cancer (HNC) are sparse. This retrospective population-based study investigated early mortality of HNC and the influence of patients’ tumor and treatment characteristics. All 8288 patients with primary HNC of the German federal state Thuringia from 1996 to 2016 were included. Statistics were performed to identify independent factors for 30-day, 90-day, and 180-day mortality. The 30-, 90-, and 180-day mortality risks were 1.8%, 5.1%, and 9.6%, respectively. Male sex, increasing age, larger tumor size, and distant metastasis, tumors of the cavity of mouth, oropharynx, and hypopharynx had a significantly greater 180-day mortality. Surgery, radiotherapy, and multimodal therapy were associated with decreased 180-day mortality. Typical factors associated with worse overall survival had the most important impact on early mortality in HNC patients in a population-based setting. Abstract Population-based studies on early mortality in head and neck cancer (HNC) are sparse. This retrospective population-based study investigated early mortality of HNC and the influence of patients’ tumor and treatment characteristics. All 8288 patients with primary HNC of the German federal state Thuringia from 1996 to 2016 were included. Univariate and multivariate analysis were performed to identify independent factors for 30-day, 90-day, and 180-day mortality. The 30-, 90-, and 180-day mortality risks were 1.8%, 5.1%, and 9.6%, respectively. In multivariable analysis, male sex (odds ratio (OR) 1.41; 95% confidence interval (CI) 1.08–1.84), increasing age (OR 1.81; CI 1.49–2.19), higher T (T4: OR 3.09; CI 1.96–4.88) and M1 classification (OR 1.97; CI 1.43–2.73), advanced stage (IV: OR 3.97; CI 1.97–8.00), tumors of the cavity of mouth (OR 3.47; CI 1.23–9.75), oropharynx (OR 3.01; CI 1.06–8.51), and hypopharynx (OR 3.27; CI 1.14–9.40) had a significantly greater 180-day mortality. Surgery (OR 0.51; CI 0.36–0.73), radiotherapy (OR 0.37; CI 0.25–0.53), and multimodal therapy (OR 0.10; CI 0.07–0.13) were associated with decreased 180-day mortality. Typical factors associated with worse overall survival had the most important impact on early mortality in a population-based setting.

Zitieren

Zitierform:
Zitierform konnte nicht geladen werden.

Rechte

Rechteinhaber: © 2022 by the authors.

Nutzung und Vervielfältigung:
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.